Isotretinoin seminar

Organised by the SFD Centre of Evidence and the Thematic Group “DEFI” (Facial Dermatoses)

Thursday 9 June 2022 from 10:20 to 17:00
Venue: Maison de la Dermatologie, 10 Cité Malesherbes, 75009 Paris
On-site: 35 places available

PROGRAMME

10:00-10:20 Welcome
10:20-10:30 Introduction – Purpose of the seminar: Olivier CHOSIDOW, Nicolas DUPIN
10:30-10:45 Isotretinoin regulatory situation: France (marketing authorisation, requirements, pharmacovigilance, compassionate prescription framework), Europe: Bernard GUILLOT, Nathalie DUMARCET

10:45-12:45 Session 1 (2 hrs)
Moderator: Bernard GUILLOT; Secretary: Florence POIZEAU
Isotretinoin prescription for acne (MA): limits of current application
- Psychiatric risks of isotretinoin, Catherine DROITCOURT (15 mins) – Patient follow-up to minimise psychiatric risks/ using the ADRS: Joëlle MICALLEF/Louise HFEZ (5 mins), followed by discussion (10 mins)
- Teratogenicity of isotretinoin
  (1) – State of affairs. How to decrease the pregnancy rate in women on isotretinoin/ discussion on the prescription of condoms and emergency contraception (cf Recommendation No. 2 of the French regulator ANSM): Annie-Pierre BERA JONVILLE (10 mins)
  (2) – Neurodevelopmental consequences: Sophie GAUTIER (5 mins)
Discussion on teratogenicity (10 mins)
- Considering the relevance of biological blood monitoring: what type, role and frequency?: Julio TANNOUS (5 mins), followed by discussion (5 mins)
- Factoring in the failure of an AB strategy in patient medium-term medical past and not in the 3 months preceding isotretinoin prescription: Florence CORGIBET, Marie BEYLOT-BARRY, Olivier CHOSIDOW (10 mins), followed by discussion (5 mins)
- Organising monthly renewal – Patient pathway and link with other health professionals: comparing GPs’, dermatologists’ (ISOLIB survey) and pharmacists’ points of view: Thibault PUSZKAREK, Nicole JOUAN, Valérie GARNIER (5 mins x 3), followed by discussion (5 mins)

Round table synthesis: all participants (20 mins)

12:45-13:30 Lunch break
**Session 2 (2 hrs)** Moderator: Florence CORGIBET; Secretary: Guillaume CHABY

**Off-label prescription of isotretinoin**

- **Acne:**
  - Moderate acne on pigmented skin (1st line): Émilie BAUBION and Antoine MAHÉ *(10 mins)*
  - Acne of the lower face in adult women (1st line for initial consultation): Fabienne BALLANGER-DESOLNEUX *(10 mins)*
  - Acne in preadolescents: Fabienne BALLANGER-DESOLNEUX *(10 mins)*
  - Prolonged, low-dose isotretinoin for chronic/recurrent/dependent/highly inflammatory acne: Marie BEYLOT-BARRY *(10 mins)*
  - Discussion *(10 mins)*

- **Rosacea failure/recurrence after well-conducted antibiotic therapy and low-dose maintenance:** Olivier CHOSIDOW *(10 mins)*, followed by discussion *(10 mins)*

- **Other facial dermatoses**
  1. Seborrheic dermatosis, mixed dermatoses, peri-oral dermatitis: Sandra LY, Olivier CHOSIDOW *(10 mins)*
  2. Verneuil disease of the face, follicular forms of Verneuil disease: Claire HOTZ, Olivier COGREL *(10 mins)*
  - Discussion *(10 mins)*

  **Round table synthesis: all participants (20 mins)**

**Break**

**Session 3 (1 hr)** Moderator: Marie BEYLOT-BARRY; Secretary: Sophie LEDUCQ

**Communication and research**

- Resistance to isotretinoin prescription: Emmanuel MAHÉ *(10 mins)*
- Disseminating recommendations: dermatologists, GPs, etc., and evaluation methods: Antoine BERTOLOTTI *(10 mins)*
- Tools to help inform health professionals and patients: Georges MARTINHO *(10 mins)*
- Place and role of the new thematic group Facial Dermatoses “DEFI” of the SFD: Sandra LY *(10 mins)*

  **Round table synthesis: all participants (20 mins)**

**Conclusion – Global summary:** Bernard GUILLOT *(15 mins)*